Related by context. All words. (Click for frequent words.) 71 prioryear 71 operatingincome 69 Azactam 68 loss NOL carryforward 68 Lidoderm R 67 DiaMed acquisition 67 THALOMID 67 OPANA franchise 67 3Q FY# 67 Normalized EPS 67 Pro forma EPS 66 adopting SFAS #R 66 PENTASA 66 noninterest expense decreased 66 millioncompared 66 Pro Forma EBITDA 66 Wellbutrin XL R 66 Individual Annuities segment 66 Kerastick 66 Recurring royalties 66 Biaxin clarithromycin 66 Voltaren Gel 65 DOVONEX 65 nonsedating antihistamine 65 ZANAFLEX CAPSULES 65 Zanaflex 65 PLAVIX R 65 PMPS brand 65 netincome 65 ended September# 65 PRAVACHOL R 65 Zanaflex tablets 65 DAC unlock 65 generic oral contraceptives 65 LIFO adjustment 65 Pro forma EBITDA 65 Novogyne 65 KADIAN ® 65 ABELCET 65 Wellbutrin XL ® 65 Adjusted Diluted EPS 65 continuingoperations 64 sumatriptan succinate 64 TEB adjustment 64 oxycodone hydrochloride extended 64 increaseof 64 Amaryl R 64 Noninterest Expense Noninterest expense 64 date Wholesale Leathercraft 64 Vancocin R 64 #.#/diluted share 64 COLAZAL R 64 Cardiac Surgery Systems 64 nine monthsended 64 Fanapt ® 64 Adjusted EBITDA1 64 ZANAFLEX tablets 64 BD Biosciences segment 64 nonoperating expense 64 LIDODERM 63 BioMarin Genzyme LLC 63 AMRIX 63 Ultane Sevorane 63 EBITDAO 63 ARCALYST ® 63 noninterest expense totaled 63 Non GAAP adjusted EBITDA 63 4Q FY# 63 HealthStream Learning 63 PLAVIX ® 63 Lilly ICOS joint venture 63 monthsended 63 Lidoderm ® 63 Amlodipine Besylate Tablets 63 fiscal# 63 ACTIQ 63 CLARINEX 63 months endedSeptember 63 SunOpta Foods 63 LIALDA MEZAVANT 63 BD Diagnostics segment 63 Adjusted Gross Profit 63 Normalized EBITDA 62 AWP litigation 62 totaled EUR#.# 62 Noninterest expense totaled 62 IMS MAT 62 operating income1 62 MA PFFS 62 Anhui Jucheng 62 Zovirax ® 62 Thalomid ® 62 CARBATROL 62 NETg acquisition 62 nonroutine income 62 PROVIGIL 62 Aloxi injection 62 OSIs 62 NOI decreased 62 Maxipime 62 REMICADE infliximab 62 Adjusted EBITDAS 62 #.# perdiluted 62 Pro forma Adjusted EBITDA 62 per dilutedshare 62 Mestinon 62 invoiced shipments 62 AmBisome 62 XOPENEX Inhalation Solution 62 Illumigen Biosciences Inc. 62 OPANA ER 62 Angiomax Angiox 62 LIFO inventory decrement 62 Zegerid OTC 62 quarterended 62 Baobaole chewable tablets 62 Paperboard Packaging segment 62 GlaxoSmithKline Imitrex 62 Sees FY# revs 62 Currency translation negatively impacted 62 Sees FY# adj EPS 62 Programmer Paradise segment 61 stock basedcompensation 61 Tussionex ® 61 Sensipar 61 adjusted EBITDAS 61 clopidogrel bisulfate 61 EBITD 61 Pro forma adjusted EBITDA 61 Segment PTOI 61 FROVA 61 Increlex R 61 USD #.#bln [001] 61 reagent disc 61 Phosphates segment 61 LIFO inventory adjustments 61 normalized FFO 61 Constant Currency 61 Clinical Diagnostics segment 61 Non GAAP Operating Margin 61 Inc. NASDAQ EVVV 61 OsmoPrep 61 Fully diluted EPS 61 Cetirizine Hydrochloride Syrup 61 Explosive Metalworking segment 61 LIFO provision 61 currency remeasurement 61 Ribavirin royalties 61 #mg dosage strength 61 PANZYTRAT 61 pro forma adjusted EBITDA 61 #compared 61 Nabumetone 61 Actimmune R 61 #.#per diluted 61 Noninterest expense decreased 61 ninemonths 61 FHLB borrowings decreased 61 Qualcomm Strategic Initiatives 61 Munghana Lonene Listenership 61 Pfizer Lyrica 61 items affecting comparability 61 proforma EPS 61 unbranded generics 61 OshKosh wholesale 61 KADIAN R 61 Equity Investees 61 Depreciation Amortization Taxes 61 Scantron segment decreased 61 Vinyls segment 61 CRIC shareholders 61 Sensipar R 61 - Non Shane Germann 61 Frova ® 61 Timeshare segment 61 dacetuzumab collaboration 61 Unfavourable Changes 61 SORL consolidated 61 nonGAAP 61 PTOI 61 TACLONEX 61 inventories revalued 61 Salix Pharmaceuticals NASDAQ SLXP 61 Zocor cholesterol lowering 61 Flector pain patch 61 JPY8 61 fuel CASM 61 Downstream CCS 61 Partnered Brands segment 61 earnings pershare 61 oral mesalamine 61 AZASITE 61 Lilly Cymbalta 61 Eloxatin ® 61 Adjusted Operating Expenses 60 Second Quarter Highlights 60 Cipralex ® 60 Pexeva 60 Retail Leathercraft 60 GAAP Adj 60 Ditropan XL 60 Abelcet 60 Exceptional Items 60 1Q FY# 60 Normalized FFO 60 Rapaflo 60 nasal corticosteroids 60 Therapeutic Antibodies segment 60 LUMIGAN R 60 Mg Uk 60 morphine sulfate extended 60 MedSurg Equipment 60 expenses totaled Ps 60 MARRIOTT REVENUES totaled 60 SangStat 60 Vivelle Dot ® 60 oral diclofenac 60 Carvedilol Tablets 60 Rx Pharmaceuticals 60 Diluted HEPS 60 Hesperion acquisition 60 Scantron segment increased 60 Q1 #F 60 Generics Segment 60 Alphagan P 60 PDP MLR 60 acquisitions divestitures transfers 60 Gabitril 60 Drivetrain segment 60 Glucophage XR 60 Tekturna HCT 60 Alphagan 60 Cold Remedy segment 60 Kerastick ® 60 MEP Joint Venture 60 Cialis Cymbalta 60 Xibrom TM 60 debt extinguishments 60 Sumatriptan 60 ASUR regulated 60 nondeductible expenses 60 Penwest Pharmaceuticals Co 60 Xalatan 60 Adjusted FIFO EBITDA 60 Auxilium Pharma 60 ARCALYST ® rilonacept 60 RAZADYNE 60 AstraZeneca Symbicort 60 netsales 60 Proleukin 60 Pro Forma Adjusted EBITDA 60 Wholesale Leathercraft 60 theprior 60 noncash goodwill impairment 60 Reimbursable costs 60 Medication Delivery 60 Adjusted Ebitda 60 Ultram ER 60 NATRECOR 60 specialty injectables 60 Yidasheng totaled RMB#.# 60 Endoscopic Technologies 60 Surface Specialties acquisition 60 Pegintron 60 Nonaccrual loans totaled 60 ev3 peripheral vascular 60 Headline PBIT 60 Vyvx Advertising Distribution 60 Aprovel R 60 Mg Usa 60 Divalproex Sodium 60 Ethyol 60 - Adjusted [023] 60 prescription dermatological 60 Biaxin XL 60 Licorice Products segment 59 Items impacting comparability 59 ECR Pharmaceuticals 59 Seroquel quetiapine fumarate 59 INEGY 59 Interest Expense Interest expense 59 INTUNIV TM 59 Recurring Adj 59 AVINZA 59 Arixtra ® 59 EBITDAA 59 ZEFFIX 59 Doryx 59 Losartan Potassium 59 Infergen R 59 undepreciated assets 59 Alaven 59 Colazal 59 Fanapt iloperidone 59 Merck Januvia 59 Gross Margin Gross 59 EBITDA1 59 Istalol 59 Soriatane R 59 RESTASIS 59 Detrol Detrol LA 59 Adoxa 59 Lexapro Effexor Serzone 59 noncash goodwill 59 Pfizer Norvasc 59 EBITANCE 59 risedronate sodium tablets 59 3Q FY# representing 59 Nicomide ® 59 Halotron revenues 59 valsartan Diovan 59 Combunox 59 thequarter ended 59 Noven Therapeutics 59 Colesevelam HCl 59 Lipitor Plavix 59 ACTONEL 59 #.#mg #mg 59 BioGlue ® 59 Visa MasterCard antitrust 59 CEDC discusses 59 QUALCOMM Strategic Initiatives 59 1Q FY# representing 59 Imputed Revenue 59 hypertension drugs Cozaar 59 angiographic outcomes 59 Seamap equipment 59 Segment EBIT 59 proforma revenues 59 pantoprazole 59 Q# revs 59 Lilly ICOS 59 Sumatriptan Succinate 59 ARCALYST R 59 RAPTIVA r 59 EBIT amounted 59 Excedrin Plavix 59 OLEPTRO ™ 59 c Calculated 59 Nuo Hua 59 endedSeptember 59 Megace ES 59 Normalised earnings 59 Targretin capsules 59 Current Installments 59 non gaap 59 EBDDT 59 RAPTIVA R 59 Effexor antidepressant 59 visit www.noven.com 59 segments Orthopaedic Implants 59 excludes unrealized gains 59 cents ashare 59 Milestone Payment 59 propoxyphene containing 59 Wellbutrin SR 59 Teveten 59 Lexiscan ® 59 plus aztreonam 59 Nascobal 59 SOLODYN R 59 totaled EUR#.#m 59 Mircette 59 RMB#.#million 59 Radix Isatidis dispersible tablets 59 RYZOLT 59 income1 59 Polymer Additives segment 59 - Adjusted [030] 59 Olefins Polyolefins 59 Adjustment Expenses 59 Azilect ® 59 Erbitux colon cancer 59 WhiteWave Alpro segment 59 ® tenofovir disoproxil 59 unaudited consolidated balance sheets 59 VANTAS 59 Soriatane 59 Normalized EBIT 59 Core FFO 59 DAC unlocking 59 Consolidated Adjusted EBITDA 59 Unusual Items section 59 Sees FY# EPS 59 ARCOXIA 59 AstraZeneca Nexium 59 RISPERDAL CONSTA 59 Opana ® 59 Sumatriptan Succinate Tablets 59 Purse TBA 59 Exterran stockholders 59 items impacting comparability 59 Vivelle Dot TM 59 Peripheral vascular 59 Fine Chemicals segment 59 Retransmission consent revenue 59 Scantron segment 59 balsalazide 59 IV Infusion Therapy 58 normalized EBIT 58 XIBROM 58 tramadol ER 58 GraftJacket R 58 Lubrizol Additives segment 58 Comparable EBITDA 58 ninemonths ended 58 temporary impairments OTTI 58 FARESTON ® 58 TOLMAR Holding Inc. 58 Optivar 58 Prozac fluoxetine 58 Sanctura 58 disposable TMR 58 interferon gamma 1b 58 Non GAAP Adjusted EBITDA 58 Repliform R revenues 58 LUCENTIS r 58 MFB Corp 58 STRIANT 58 MEVACOR 58 RAPTIVA 58 Goodwill Impairment Charge 58 Unallocated Corporate 58 unconsolidated joint 58 Hectorol 58 Amnesteem 58 PROTONIX 58 BioGlue revenues 58 Comparable Basis 58 Components Segment 58 2Q FY# representing 58 #.#bn rub [004] 58 unfavorable variance 58 excludes acquisitions divestitures 58 Pro Forma EPS 58 Bone Graft Substitutes 58 Womacks Adjusted EBITDA 58 Androgel R 58 Kyowa Kirin 58 Contingent Consideration 58 Predecessor Period 58 IV Busulfex 58 MSEK -#.# 58 Rebif multiple sclerosis 58 IAROC 58 Including discontinued operations 58 adjusted1 58 adjusted OIBDA margin 58 Mircette R 58 Brooks Eckerd drugstores 58 Proforma adjustments 58 VYTORIN ezetimibe simvastatin 58 Ultracet R 58 Evoclin R 58 Residential Furnishings 58 CHF#.# [001] 58 SFAS# R 58 Xenazine ® 58 9M FY# [002] 58 Clarithromycin sustained release 58 OLUX 58 income teb 58 oxycodone CR 58 Nonperforming loans decreased 58 Hugoton Properties 58 XYREM 58 intersegment eliminations 58 INTEGRILIN 58 AVINZA ® 58 Wholesale Leathercraft posted 58 revenues excluding nonrecurring 58 SEK -#.# -#.# [003] 58 Oxandrin 58 excluding goodwill impairment 58 pain relievers Duragesic 58 Paliperidone ER 58 Neulasta R 58 fexofenadine hydrochloride 58 Vishay stockholders 58 UCB Keppra 58 quarter offiscal 58 Background Screening segment 58 Vimpat R 58 palonosetron hydrochloride injection 58 Pro Forma Revenues 58 quinapril 58 Unlevered Cash Flow 58 AstraZeneca Toprol XL 58 Aciphex R 58 Travatan 58 International Liftboats 58 Unaudited Condensed Consolidated 58 Ortho McNeill 58 LIFO adjustments 58 Combigan 58 ZALBIN ™ 58 threemonths ended 58 ApothecaryRx 58 Compensation Expense 58 Hectorol R 58 Humira adalimumab 58 including Percocet Xanax 58 generic Valtrex 58 Broadspire segment 58 SEK #.#M #.# 58 EPOGEN R 58 DuoNeb 58 Cytogen marketed 58 endedDecember 58 Ps.3 58 Orapred 58 metoprolol succinate 58 SEK -#.# [002] 58 Business.com Acquisition 58 International Leathercraft 58 neurosurgery extremity reconstruction 58 Pfizer Zoloft 58 Bayer Yasmin 58 Successor Period 58 Lidoderm 58 ascompared 58 hydrochloride tablets 58 Zeneus 58 Bristol Myers Squibb Pravachol 58 excluding divestments 58 EBIAT 58 deductible goodwill impairment 58 Refractories segment 58 totaled USD#.#m 58 CIP TRAMADOL ER 58 Sees Q# 58 GlaxoSmithKline Lamictal 58 Professional Instrumentation 58 Prepaid churn 57 Zyprexa olanzapine 57 comparedto 57 nonoperating income 57 Danazol 57 Aldara ® 57 SmartGrowth Deposits 57 GAAP EARNINGS 57 Sanctura XR 57 Chemicals Segment 57 QUADRAMET R 57 RECOTHROM R 57 Selling Expenses 57 Klean Prep TM 57 sameperiod 57 Concateno plc 57 Integra Lifesciences 57 Lodging Reported EBITDA 57 JasmineSola brand 57 Billable headcount 57 Astepro 57 Sporanox 57 Dovonex 57 Hycamtin ® 57 FENTORA 57 Somatuline R Depot 57 BioGlue R 57 Dostinex 57 Wireline adjusted EBITDA 57 Tikcro Technologies Reports 57 Penwest Pharmaceuticals 57 BUPHENYL R 57 Consolidated adjusted EBITDA 57 Azmacort R 57 Nascobal ® 57 Dorzolamide 57 PULMICORT 57 - - Total [058] 57 Operating Expenses Operating 57 - Adjusted [034] 57 Invested assets 57 -T#/T# 57 Adjusted EBTIDA 57 EUR -#.# [001] 57 acquired Brooks Eckerd 57 include ClindaReach TM 57 nonperforming assets totaled 57 CAELYX 57 DAC offsets 57 noncash impairments 57 Compensation Expenses 57 Launches Generic Version 57 FAS# R 57 Excluding nonrecurring items 57 SFAS#R 57 REVENUE Revenue 57 Overall NewMarket 57 USD#.#m USD#.# [002] 57 Valacyclovir 57 LIFO inventory valuation 57 Orthopaedic Implants 57 FIFO EBITDA 57 antihistamine Zyrtec 57 - #,#.# #,#.# [002] 57 museum Julie Setlock 57 XAGRID 57 Prozac Paxil Zoloft 57 Motorhome Resorts Segment 57 UNITS SOLD 57 ONTAK 57 OPANA 57 Gross Profit Gross 57 Milestone Payments 57 Non GAAP EPS 57 adjusted EBITDAR 57 Comparable bakery cafe 57 intangible impairment 57 Efudex 57 Advate 57 Taxable equivalent 57 Comparable RevPAR 57 Eraxis 57 Supplemental Schedules 57 reports Q4 adj 57 VANTAS R 57 Onco TCS 57 Allegra ® 57 Generic Protonix 57 SUMMARY INCOME STATEMENTS 57 unrealized derivative 57 Resilient Flooring 57 AmericanSingles segment 57 Ferrellgas annualized 57 R hylan GF 57 Arana Therapeutics Limited 57 Wyeth Advil 57 USD#.#m USD#.# per [002] 57 Seroquel quetiapine 57 EBITDAC 57 Acquisitions Divestitures 57 Iscover 57 Nine Months Months 57 MetroGel R 57 OIBDAN declined 57 noncash pretax charge 57 Orthopedic Implants 57 early extinguishments 57 Unitrin Direct segment 57 CHF#.# billion [002] 57 Vicuron Pharmaceuticals 57 Detrol LA 57 Polymeropoulos 57 Sirton 57 Recurring FFO 57 REAL ESTATE BUSINESS 57 BLU U R 57 kroner euro#.# [002] 57 Aplenzin 57 GYN Surgical 57 No. #R 57 Consolidated EBITDAR 57 Tecstar Automotive Group 57 excluding BIBP 57 Benazepril 57 Forlax R 57 Exforge HCT 57 paroxetine Paxil 57 Global Generics 57 SUSTIVA R 57 RMB2 #.# 57 OREO valuation 57 EPADS 57 Filgrastim 57 Q#/FY# 57 Ginkor Fort ® 57 Apco Argentina Reports 57 XOPENEX 57 From Operations AFFO 57 Variable Interest Entities VIEs 57 SOLODYN 57 Nisisco R 57 oxcarbazepine 57 c Includes 57 Non Dilutive 57 Somatuline Depot 57 Diluted EPS Guidance 57 gallium arsenide GaAs substrate 57 USD #.#mln 57 Underlying pretax 57 Synalloy Corporation Announces 57 Pharmacokinetic parameters 57 Lillie Rubin chain 57 oral contraceptive Yasmin 57 Prandin 57 marketed workover rigs 57 Tekturna aliskiren 57 Nasdaq KOSP 57 SUPPRELIN LA 57 Omnicare pharmacy 57 Zemplar 57 AndroGel R 57 DORYX 57 thethird quarter 57 INVEGA ® SUSTENNA ® 57 MSR hedging 57 pretax goodwill impairment 57 Excluding goodwill impairment 57 adjusted distributable cash 57 - Revenues [006] 57 Ortho Cept 57 Earnings Per Diluted 57 Reconciling Items 57 Acquisition Related 57 Adjusted EBIT 57 generic Depakote 57 Oxandrin R 57 Orapred ODT 57 Opana R 57 SG &A; 57 MoxDuo TM IR 57 glatiramer 57 DPP4 57 Proquin XR 57 Sustiva efavirenz 57 SYNERGY Stent 57 GLUMETZA 57 GlaxoSmithKline Zofran 57 Sees FY# revenues 57 Eligard ® 57 Non IFRS 57 Infergen 57 cholesterol reducer Zocor 57 Medicare Advantage MLR 57 Visiting Nurse VN 57 Bupropion HCl ER 57 AGY Asia 57 TOFUTTI BRANDS INC. 57 Depakene 57 OICM turnover totaled 56 BioDelivery Sciences NASDAQ BDSI 56 Renagel 56 metformin hydrochloride 56 Summarized consolidated 56 Megace R ES 56 Newsstand Distribution Services 56 Fazenda Brasileiro Mine 56 Competitive Wireline 56 - Non GAAP [031] 56 SUPPRELIN R LA 56 DNOI 56 Pigments segment 56 Depletions 56 Frova R 56 Nasacort 56 equity accounted investees 56 Vivelle Dot 56 ABILIFY R 56 LifeVantage Announces 56 Testim R 56 PGP Acquisition 56 thousand BOEPD 56 Tritace 56 Quinapril 56 Bilive 56 DJO Merger 56 CYCLOSET 56 Pravachol cholesterol lowering 56 Par Pharma 56 Adjusted Non GAAP 56 Churn Rate 56 Lipofen 56 ZEGERID Capsules 56 EUR -#.# -#.# [001] 56 Covered Loans 56 Derivative Liabilities 56 Non Dilutive Financing 56 oral hypoglycemic agent 56 Fluticasone Propionate Nasal Spray 56 Fabricated Products segment 56 unbilled revenue 56 placebo dexamethasone 56 Zerit 56 nonmedically 56 Anesthesia Disposables 56 Maintenance Capital Expenditures 56 Accupril 56 EpiPen Auto Injector 56 PRIALT 56 Kos Pharma 56 NEUPOGEN R 56 Shire BioChem Inc. 56 levalbuterol 56 Adcirca 56 Effexor venlafaxine 56 noncash accounting 56 foreign currency remeasurement 56 TIMERx 56 Lilly Zyprexa 56 #were 56 Zovirax R 56 GRALISE 56 FAS #R expense 56 Chlor Alkali segment 56 Humalog insulin 56 - -OfficeMax ImPress R 56 Restruct 56 alfuzosin 56 SEK#.#m [001] 56 -Ganga aarti 56 -By Cliodhna McGowan 56 intersegment revenues 56 c Relates 56 Specialized Products 56 Biaxin 56 NutropinAq ® 56 Visicol 56 Craftmade segment 56 Forlax ® 56 Announces Tentative Approval 56 CASM decreased 56 Adjusted EBITDAR margin 56 Zyflo CR 56 Walgreen 2Q 56 tramadol HCl 56 Reported Adj 56 Atria Genetics 56 Adjusted diluted 56 Oxytrol R 56 Nonoperating 56 Ferrlecit 56 #.Net 56 CHF #.#M 56 lorazepam Ativan 56 loss carrybacks 56 Items Affecting Comparability 56 vildagliptin 56 FAS CAS Pension 56 balsalazide disodium Capsules 56 Cardiolite 56 Prescriptions filled 56 please visit http:/www.atherogenics.com 56 Dronabinol 56 Gross Margin Percentage 56 Agenerase 56 H1 FY# [001] 56 mequinol 56 Adjusted Operating Margin 56 Drug eluting stent 56 azelastine 56 ADDERALL XR 56 adjusted EBITA 56 Matches Estimate 56 Evaporative Cooling segment 56 Byproduct revenues 56 depreciation amortization accretion 56 FFO payout ratio 56 Advicor 56 LOGIX SA 56 Convertible Subordinated Debt 56 Mortgage loan fundings 56 Engineered Materials segment 56 Yasmin oral contraceptive 56 Normalized Funds 56 levocetirizine 56 Anika Therapeutics 56 NEUPOGEN 56 ENTOCORT EC 56 CytoGam 56 MERREM IV 56 CLP#.# trillion 56 Medicis Pharma 56 Encysive surged 56 EURO#.# [002] 56 Salix Pharma 56 ALTANA Chemie 56 VISICOL R 56 MANAGEMENT DISCUSSION AND ANALYSIS 56 CNOA shareholders 56 generic oxaliplatin 56 bln.togrogs 56 poor metabolizers 56 - -Belusko 56 Stavzor 56 Submitted Pursuant 56 MetroGel 56 ALTACE 56 Q2 FY# [001] 56 Favourable Changes total 56 Viatris 56 ended December# 56 Trelstar R 56 Adjusted EPS 56 USD#.#m [007] 56 ethinyl estradiol tablets USP 56 soft gelatin capsule 56 Glucotrol XL 56 Pressure Sensitive Materials 56 Cetrotide R 56 b Excludes 56 NanoKnife IRE System 56 Lansoprazole 56 CRINONE 56 Pretax Income 56 Ambien CR TM 56 generic Adderall XR 56 adopting SFAS 56 EUR#.#bn [004] 56 AMPAC ISP Holdings 56 EBITA amounted 56 MSEK -# [002] 56 PCRX 56 USOGP 56 Segment adjusted OIBDA 56 IBNR reserve 56 Paladin Labs 56 - Revenues [016] 56 Nitoman 56 Lithobid 56 No. #R SFAS 56 #M/# 56 adj EPS 56 Postpay ARPU 56 Diastat 56 ALPMF 56 Abbott Humira 56 Miscellaneous Manufacturing 56 Nexium esomeprazole 56 RLEC adjusted EBITDA 56 Cortoss 56 Annualized ROE 56 Affirms FY# 56 Viagra Soft Cialis Soft 56 ofapproximately 56 PROMUS 56 excluding nonrecurring 56 Standardized distributable cash 56 - - [020] 56 Ps.#.# [006] 56 PLN #.#m [001] 56 -Subscribes 56 Astelin 56 - - Non GAAP [007] 56 BOEd 56 Lipofen R 56 aftertax gain 56 accumulated undistributed 56 thalidomide Thalomid 56 MDS Proteomics 56 PharmaSwiss SA 56 Non GAAP Diluted EPS 56 Corporate Overhead 56 Angelini Labopharm 56 Levetiracetam Tablets 56 n#.# [002] 56 Saehan Bancorp Reports 56 SEASONALE R 56 INSPIRE Trial Phase III 56 amifostine 56 Based Compensation Expense 56 Revises FY# 56 fusion enhancers 56 Preclinical eValuation 56 Enventis Sector 56 EHT AGN 56 Actimmune ® 56 diluted EPS 56 gp# vaccine 56 adjusted ebitda 56 Q4 adj EPS 56 currency translations 56 Pro Forma Operating 56 blockbuster antidepressant Effexor 56 Steiner Leisure NASDAQ STNR 56 pershare 56 topical NSAID 56 Payment FAS #R 56 Angio Seal royalties 56 EDITDA 56 Engineered Material Systems 56 Toprol 56 Oilseeds Processing operating 56 - Babelgum Online 56 Reyataz atazanavir 56 Maintains FY# 56 financialstatements 56 Delsym 56 Fumarate 56 Venlafaxine 56 LOVENOX R 56 Starlix 56 Distributions Distributions 56 STECO acquisition 56 Janumet 56 Cariprazine 56 BioFuel Reports 55 Generic Versions 55 Operational EBITDA 55 consolidated OIBDA 55 AUDIOCODES LTD 55 ZOCOR 55 Impairment Losses 55 Rebif ® 55 Pulmicort Respules 55 2Q FY# [001] 55 EPS Excl 55 crore QoQ